Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 32

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 32
---
, and from March 2011 to December 2011, he also served as Director, Scientific Licensing Assessment, identifying and evaluating business development opportunities in the neuropsychiatric therapeutic area including autism and ADHD. Prior to entering the biopharmaceutical industry, Dr. Rubin was in private practice as a developmental-behavioral pediatrician for 16 years. Before entering private practice, Dr. Rubin was a pediatric resident at Albert Einstein/Montefiore Hospital in the Bronx, New York and a fellow in ambulatory pediatrics at Boston’s Children Hospital. Dr. Rubin received his M.D. from the University of Connecticut School of Medicine, his Master of Business Administration from the Columbia School of Business and his Bachelor of Science in molecular biophysics and biochemistry from Yale University. 20 COMPENSATION DISCUSSION AND ANALYSIS Introduction The Compensation Discussion and Analysis that follows provides a description of our compensation program as well as the compensation for each of the individuals listed below. We refer to these individuals throughout the Compensation Discussion and Analysis and the tables and narratives that follow as our Named Executive Officers, or NEOs. For 2024, our named executive officers were as follows: • Jack A. Khattar, Chief Executive Officer, President & Secretary • Timothy C. Dec, Senior Vice President, Chief Financial Officer • Jonathan Rubin, MD, Senior Vice President, Chief Medical Officer, Research and Development • Padmanabh P. Bhatt, Ph.D., Senior Vice President of Intellectual Property, Chief Scientific Officer • Frank Mottola, Senior Vice President of Quality, GMP Operations, Information Technology and Regulatory Affairs Executive Compensation Philosophy; Say on Pay Support Our executive compensation program is designed to align the interests of our NEOs and all other executive officers with those of our stockholders by rewarding executives with incentives that are closely linked to the Company’s achievement of short-term and long-term business objectives. The program is focused on successfully attracting and retaining highly qualified and motivated executives and providing compensation levels and programs that are competitive with comparably sized pharmaceutical and biotechnology companies in the United States. The Compensation Committee seeks to deliver a competitive compensation program to retain and motivate our executives by rewarding their contributions and the value they create for all of our stockholders. As described below, an independent compensation consultant assists our Compensation Committee in this process. At our 2024 Annual Meeting of Stockholders, stockholders voted overwhelmingly in favor of our compensation program for our NEOs through our annual “Say-on-Pay vote” with more than 95% of votes cast approving the